2025-12-06 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data, following your requested format:

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **JNJ Overview:** Johnson & Johnson is a diversified healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

*   **Return Rate Comparison:**
    *   JNJ Cumulative Return: 58.25%
    *   VOO (S&P 500) Cumulative Return: 100.58%
    *   Divergence: -42.0 (Current Relative Divergence: 28.6)

*   **Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the given period. The current divergence of -42.0 indicates substantial underperformance. The relative divergence of 28.6 suggests the underperformance is closer to the historical low end than the high end.

*   **Alpha/Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 331.7 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 306.3 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 346.3 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 373.6 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 406.1 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 419.3 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 372.1 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 343.3 |
| 2023-2025  | 29.0% | 79.6% | -36.0% | 0.1 | 487.4 |

*   **Analysis of Alpha/Beta:**
    *   **Alpha:** Alpha is consistently negative, indicating JNJ's underperformance compared to its benchmark, except for the 2020-2022 period. The recent years (2021-2025) show significant negative Alpha.
    *   **Beta:** Beta is generally low, around 0.1 to 0.5, suggesting JNJ has lower volatility than the market.
    *   **CAGR:** CAGR varies significantly, with recent periods showing negative growth (2021-2024) and a rebound in 2023-2025.
    *   **MDD:** The Maximum Drawdown (MDD) is high, indicating substantial potential for losses during specific periods.

**2) Recent Stock Price Fluctuations**

*   Close: 205.33
*   Last Market: Price= 202.33, Previous Close = 202.48, Change = -0.07
*   5-day SMA: 206.04
*   20-day SMA: 198.97
*   60-day SMA: 189.77

*   **Analysis:** The current price (202.33) is slightly below the 5-day SMA (206.04), suggesting a short-term pullback. The 5-day SMA is above the 20-day SMA (198.97), which is above the 60-day SMA (189.77). This indicates an upward trend, but with potential for short-term volatility.

**3) RSI, PPO, Divergence, and Expected Return**

*   Market Risk Indicator (MRI): 0.8 (Medium Investment Recommended)
*   RSI: 78.93
*   PPO: 0.11
*   Hybrid Signal: cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-03)
*   Recent (20 days) relative divergence change: -6.4 (단기하락 - Short-term decline)
*   Expected Return: -56.9%

*   **Analysis:**
    *   **MRI:** A value of 0.8 suggests a medium level of investment risk.
    *   **RSI:** RSI above 70 (78.93) indicates that the stock is overbought, potentially signaling a pullback in the near term.
    *   **PPO:** A PPO of 0.11 indicates positive momentum, but it's relatively close to zero, suggesting it may not be a strong trend.
    *   **Hybrid Signal:** Indicates a buy signal with limited cash holding, aligning with the medium MRI.
    *   **Divergence Change:** The recent negative change in relative divergence (-6.4) confirms short-term underperformance relative to the comparison stock.
    *   **Expected Return:** The very negative expected return (-56.9%) is a major red flag, suggesting significant potential losses if held long-term.

**4) Recent News & Significant Events**

*   **Positive Headlines:**
    *   Barclays Raises JNJ Price Target
    *   New Analyst Forecast: $227 Price Target
    *   SCS Capital Management LLC Bought Shares
    *   Johnson & Johnson Stock Surges on Strong Earnings and Strategic Acquisition

*   **Neutral/Cautious Headlines:**
    *   Is It Too Late To Consider Johnson & Johnson After Its 40.6% 2025 Rally?
    *   Why Johnson & Johnson's Share Price Is Popping This Month

*   **Analysis:** Recent news is a mixed bag. Several articles highlight positive analyst ratings and price target increases, suggesting confidence in the company's future. However, other headlines question whether the stock's recent rally has made it overvalued and point out potential risks.

**4-2) Analyst Opinions**

*   Consensus: Buy (Mean: 2.16)
*   Target Price: Avg: 203.42 / High: 230.00 / Low: 155.00

*   **Analysis:** While the analyst consensus is a "Buy", the average target price of 203.42 is only slightly above the current price (202.33), and the lowest price target is significantly lower, suggesting there may be some disagreement among analysts regarding the stock's potential.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-22 | 2.14 | 23.99 B$    |
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2025-10-22 | 1.12 | 22.47 B$    |

*   **Analysis:** The most recent EPS is 2.14 with 23.99B$ revenue. The EPS has fluctuated significantly, with a high of 4.57 and a low of 1.12. Revenue has been relatively stable, hovering around $22-24 billion.

**6) Financial Information (Revenue/Profitability and Capital/Profitability)**

*   **Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $23.99B   | 69.56%        |
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |

*   **Capital and Profitability:**

| Quarter    | Equity    | ROE   |
|------------|-----------|-------|
| 2025-09-30 | $79.28B   | 6.50% |
| 2025-06-30 | $78.47B   | 7.06% |
| 2025-03-31 | $78.11B   | 14.08%|
| 2024-12-31 | $71.49B   | 4.80% |
| 2024-09-30 | $70.16B   | 3.84% |

*   **Analysis:**
    *   **Revenue and Profitability:** Revenue has been relatively consistent, with a slight increase in the most recent quarter. Profit margins are strong, consistently above 66%.
    *   **Capital and Profitability:** Equity has steadily increased. ROE (Return on Equity) has fluctuated, with a spike in 2025-03-31.

**7) Comprehensive Analysis (Summary)**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Mixed Signals:** Technical indicators provide conflicting signals, with RSI indicating overbought conditions, while the PPO shows positive momentum.
*   **Analyst Disagreement:** Analyst consensus is "Buy", but target prices vary, and the average target price offers limited upside.
*   **Recent News:** Recent news is a mix of positive analyst sentiment and questions about valuation.
*   **Expected Return Warning:** The most concerning factor is the extremely negative expected return (-56.9%), suggesting substantial potential losses.
*   **Financials:** Revenue and profit margins are solid.

**Overall Recommendation:**

Based on the provided data, a cautious approach to investing in JNJ is warranted. While the company has a strong financial foundation, the negative expected return, underperformance compared to the S&P 500, and overbought technical indicators suggest potential risks. Further investigation into the factors driving the negative expected return is highly recommended before making any investment decisions. The short-term positive news might be already priced into the stock, and the potential downside risk seems significant.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.